



Self-Injectable Epinephrine Agents

Therapeutic Class Review (TCR)

March 10, 2014

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Suite 201
Cincinnati, Ohio 45242

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.

FDA-APPROVED INDICATIONS^{1,2,3,4}

Drug	Manufacturer	FDA-Approved Indications
epinephrine 0.3 mg (Adrenaclick®, Auvi-Q™, Epi Pen®)	generic* Amedra Sanofi-Aventis Mylan	<ul style="list-style-type: none"> ▪ Emergency treatment of Type I allergic reactions including anaphylaxis to stinging insects, biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens ▪ Emergency treatment of idiopathic anaphylaxis ▪ Emergency treatment of exercise-induced anaphylaxis
epinephrine 0.15 mg (Adrenaclick®, Auvi-Q™, Epi Pen Jr.®)	generic* Amedra Sanofi-Aventis Mylan	<ul style="list-style-type: none"> ▪ Emergency treatment of exercise-induced anaphylaxis

*The generic epinephrine is an authorized generic of Adrenaclick.

OVERVIEW

Anaphylaxis is an acute, life-threatening medical emergency with many potential triggers. According to the 2010 diagnosis and management of anaphylaxis practice parameter, anaphylaxis is currently defined as one of three scenarios:

- The acute onset of a reaction (minutes to hours) with involvement of the skin, mucosal tissue, or both and at least one of the following: a) respiratory compromise; or b) reduced blood pressure or c) symptoms of end-organ dysfunction;
- Two or more of the following that occur rapidly after exposure to a likely allergen for that patient – involvement of the skin/mucosal tissue, respiratory compromise, reduced blood pressure or associated symptoms, and/or persistent gastrointestinal symptoms; or
- Reduced blood pressure after exposure to a known allergen.⁵

Anaphylaxis may be fatal and requires prompt recognition and immediate management.⁶ Anaphylaxis has a rapid onset with multiple organ-system involvement and is primarily seen in sensitized individuals after exposure to specific antigens. Reactions typically follow a uniphasic pattern; however, about 20 percent of reactions will be biphasic in nature. The second phase usually occurs after an asymptomatic period of one to eight hours with as much as a 24 hour delay. According to the 2010 National Institute of Allergy and Infectious Diseases (NIAID)-Sponsored Food Allergy Guidelines, intramuscular epinephrine is the treatment of choice for all instances of anaphylaxis resulting from food or any other cause.⁷ It should be administered immediately at first signs or symptoms of anaphylaxis. Although epinephrine has a rapid onset of action, it is also quickly metabolized. Therefore, repeat dosing may be necessary if anaphylactic symptoms do not fully resolve in five to 15 minutes. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Protracted anaphylaxis may persist beyond 24 hours. Concurrent beta-blocker therapy may adversely affect the response to management. Secondary measures include circulatory support, antihistamines (both H₁ and H₂ antagonists), corticosteroids, and, occasionally, bronchodilators. Careful post-treatment observation of patients who suffer an anaphylactic episode is necessary with ready access to emergency care for the following 48 hours. Patients who experience hypotension should remain recumbent until hemodynamically stable or asymptomatic, due to an increased risk of sudden death upon sitting upright prematurely.⁸

Anaphylaxis may occur as a result of exposure to specific agents (e.g., food, medication, or insect bites/stings).⁹ Patients should be educated about specific exposures that may place them at risk for

future reactions. They should also be provided counseling on avoidance measures to reduce risk for such exposures. Patients who have had anaphylaxis should carry self-injectable epinephrine for emergency use. These patients should also carry identification indicating they are prone to anaphylaxis and indicate the responsible agent.

PHARMACOLOGY¹⁰

Epinephrine acts on both alpha and beta adrenergic receptors. By acting on the alpha adrenergic receptors, epinephrine reduces vasodilation and increases vascular permeability that occurs during anaphylaxis which alleviates loss of intravascular fluid volume and hypotension. Through its action on beta adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation which alleviates bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis. Epinephrine may also be useful in reducing urticaria, pruritus, angioedema, and gastrointestinal/genitourinary symptoms associated with anaphylaxis as a result of its relaxing effects on the smooth muscle of the stomach, intestines, uterus, and urinary bladder.

PHARMACOKINETICS¹¹

Drug	Route of Administration	Onset of Action	Duration of Action
epinephrine (AdrenaClick, Auvi-Q, Epi Pen, Epi Pen Jr.)	SC	Five to 15 minutes	One to four hours
	IM	Variable	One to four hours

CONTRAINDICATIONS/WARNINGS^{12,13,14,15}

There are no absolute contraindications for use of epinephrine in life-threatening situations; however, patients with cardiovascular disease and metabolic disorders are more prone to adverse effects when using self-injectable epinephrine. Thus, epinephrine should be administered with caution in such patients. AdrenaClick, Auvi-Q, Epi Pen, and Epi Pen Jr. contain sulfites. The presence of a sulfite in these products should not deter administration of the drug for treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive. Another precaution that should be addressed when using epinephrine self-injectable products is to avoid accidentally injecting into one's fingers, hands, or feet because this could cause vasoconstriction resulting in a loss of blood flow and hypothermia in the affected area and may require medical attention.

DRUG INTERACTIONS^{16,17,18,19,20}

Epinephrine should be used cautiously in patients receiving any of the following drugs due to the increased risk of adverse effects, including cardiac arrhythmias: albuterol, dobutamine, dopamine, isoproterenol, metaproterenol, norepinephrine, phenylephrine, phenylpropranolamine, pseudoephedrine, ritodrine, salmeterol, and terbutaline. Certain types of antidepressants, such as tricyclic antidepressants and monoamine oxidase inhibitors, along with thyroid hormone replacement, may also potentiate epinephrine physiological effects. Likewise, beta-adrenergic blocking drugs, such as propranolol and ergot alkaloids, may antagonize the cardio stimulating effects of epinephrine.

ADVERSE EFFECTS^{21,22,23,24}

Adverse reactions to epinephrine may include transient CNS symptoms, such as moderate anxiety, apprehensiveness, restlessness, tremor, dizziness, and/or headache. Other adverse effects may include sweating, palpitations, pallor, nausea/vomiting, and/or respiratory difficulties. Although these reactions may occur in patients receiving therapeutic doses, they are more likely to occur in patients with hypertension or hyperthyroidism. Cardiovascular adverse effects, such as arrhythmias and rapid rises in blood pressure, have been observed in patients receiving epinephrine products. Arrhythmias, such as ventricular fibrillation, have been reported and have been fatal in some instances in patients with underlying cardiac disease or utilizing certain drugs. Furthermore, rapid increases in blood pressure have produced cerebral hemorrhage, particularly in elderly patients with underlying heart disease. Angina may develop and/or worsen in patients with coronary artery disease. Diabetic patients may experience an increase in blood glucose levels following administration of epinephrine. Patients with Parkinson's disease may notice a temporary worsening of symptoms. It should be noted that, in an acute life-threatening allergic reaction, the potential for epinephrine to produce the types of adverse reactions stated above, does not contraindicate its use.²⁵

SPECIAL POPULATIONS^{26,27,28,29}

Geriatrics

Elderly patients are more prone to adverse effects when using epinephrine and should therefore use self-injectable epinephrine with caution. This is especially true for geriatric patients with underlying cardiovascular and/or metabolic disease.

Pediatrics

The self-injectable epinephrine products in this category are approved for use in children based on body weight. Please consult the individual package inserts for specific product information.

Pregnancy

Epinephrine is Pregnancy Category C.

Renal Impairment

There are no specific recommendations for dosage adjustments necessary for patients with impaired renal function. Please consult the individual package inserts for specific product information.

Hepatic Impairment

There are no specific recommendations for dosage adjustments necessary for patients with impaired hepatic function. Please consult the individual package inserts for specific product information.

DOSAGES^{30,31,32,33}

Drug	Patient Weight of 30 kg or more (66 pounds or more)	Patient Weight of 15 to 30 kg (33 to 66 pounds)	Availability Special Note: Inject IM or SC in the anterolateral aspect of the thigh, through clothing if necessary. Time to Cmax is shortest when administered IM to the lateral aspect of the thigh. ³⁴
epinephrine (Adrenaclick, Auvi-Q, Epi Pen, Epi Pen Jr.)	0.3 mg injection	0.15 mg injection	<p>Adrenaclick and generic: 0.15 mg/0.15 mL, 0.3 mg/0.3 mL</p> <ul style="list-style-type: none"> ▪ 0.15 mg/0.15 mL, 0.3 mg/0.3 mL; each strength packaged with two auto-injectors; training devices for the generic are available to order ▪ Individual devices are intended for a single administration, remaining volume should be discarded; more than two subsequent doses should be administered under direct medical supervision <p>Auvi-Q: 0.15 mg/0.15 mL, 0.3 mg/0.3 mL</p> <ul style="list-style-type: none"> ▪ Auvi-Q 0.15 mg and Auvi-Q 0.3 mg are available with two auto-injectors and a single Auvi-Q trainer device ▪ Each device is intended for a single administration, although the trainer device may be used multiple times; repeat injections may be necessary with an additional Auvi-Q; however, more than two subsequent doses should be administered under direct medical supervision <p>Epi Pen 0.3 mg (0.3 mL; 1:1000)</p> <p>Epi Pen Jr. 0.15 mg (0.3 mL; 1:2000)</p> <ul style="list-style-type: none"> ▪ Dual packs of both Epi Pen and Epi Pen Jr. (Epi Pen 2-Pak and Epi Pen Jr 2-Pak) are available with two auto-injectors and one auto-injector trainer device ▪ Individual devices are intended for a single administration, remaining volume should be discarded; more than two subsequent doses should be administered under direct medical supervision

Adrenaclick, Auvi-Q, Epi Pen, and Epi Pen Jr., are only available as double packs. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

DEVICES^{35,36,37,38}

These products are intended for immediate self-administration as emergency supportive therapy only and are not a substitute for immediate medical care.

Epinephrine injection and Adrenaclick auto-injectors each contain 1.1 mL of epinephrine solution, delivering either 0.15 mg (0.15 mL) or 0.3 mg (0.3 mL) of epinephrine in a single administration. The remaining volume should be discarded.

Auvi-Q 0.3 mg and Auvi-Q 0.15 mg each contain 0.76 mL epinephrine solution. When activated, 0.3 mL and 0.15 mL epinephrine solution is dispensed, for Auvi-Q 0.3 mg and Auvi-Q 0.15 mg, respectively. Any remaining solution should be discarded.

Epi Pen and Epi Pen Jr. Auto Injectors each contain two mL of epinephrine solution. Approximately 1.7 mL remains unusable after activation. Each Epi Pen delivers 0.3 mg epinephrine in a single dose. Each Epi Pen Jr. delivers 0.15 mg epinephrine in a single dose.

Epi Pen, Epi Pen Jr, Adrenaclick, and epinephrine auto-injectors contain visual instructions on the devices. Auvi-Q devices include visible cues through LED lights, audible beeps, and electronic voice instructions for use.

CLINICAL TRIALS

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, comparative, controlled trials comparing agents within this class for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.

There are no comparative trials currently available for the self-injectable epinephrine products.

SUMMARY

Anaphylaxis is a life-threatening allergic reaction that can be caused by a variety of allergens including food, medications, insect stings and bites, and latex. All patients at risk of anaphylaxis are urged to carry self-injectable epinephrine (Adrenaclick, Auvi-Q, Epi-Pen, or Epi-Pen Jr.). Patients should be well informed by their physician and/or pharmacist of when to use this life saving medication.

Each of the self-injectable epinephrine devices allows patients to deliver a single dose from one unit via auto-injection. The Auvi-Q device guides patients and caregivers through the injection process with audio and visual cues.

REFERENCES

- 1 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 2 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 3 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 4 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 5 Lieberman P, Nicklas RA, Oppenheimer J, Kemp SR, Lang DM, et al. Diagnosis and management of anaphylaxis practice parameter: 2010 update (article in press). *J Allergy Clin Immunol.* 2010; doi:10.1016/j.physlethb.2003.10.071. Available at: <http://www.aaaai.org/practice-resources/Statements-and-Practice-Parameters/Practice-parameters-and-other-guidelines-page.aspx>. Accessed March 5, 2014.
- 6 Ellis AK and Day JH. Diagnosis and management of anaphylaxis. *CMAJ.* 2003; 169(4):307-311. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12925426>. Accessed March 5, 2014.
- 7 Boyce JA, Asa'ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-Sponsored Expert Panel. *J Allergy Clin Immunol.* 2010; 126 (6 Supp): S1-S8. Available at: <http://www.niaid.nih.gov/topics/foodallergy/clinical/Pages/default.aspx>. Accessed March 5, 2014.
- 8 Lieberman P, Nicklas RA, Oppenheimer J, Kemp SR, Lang DM, et al. Diagnosis and management of anaphylaxis practice parameter: 2010 update (article in press). *J Allergy Clin Immunol.* 2010; doi:10.1016/j.physlethb.2003.10.071. Available at: <http://www.aaaai.org/practice-resources/Statements-and-Practice-Parameters/Practice-parameters-and-other-guidelines-page.aspx>. Accessed March 5, 2014.
- 9 Lieberman P, Nicklas RA, Oppenheimer J, Kemp SR, Lang DM, et al. Diagnosis and management of anaphylaxis practice parameter: 2010 update (article in press). *J Allergy Clin Immunol.* 2010; doi:10.1016/j.physlethb.2003.10.071. Available at: <http://www.aaaai.org/practice-resources/Statements-and-Practice-Parameters/Practice-parameters-and-other-guidelines-page.aspx>. Accessed March 5, 2014.
- 10 Gold Standard, Inc. Epinephrine. Clinical Pharmacology [database online]. Available at: <http://www.clinicalpharmacology.com>. Accessed March 5, 2014.
- 11 Gold Standard, Inc. Epinephrine. Clinical Pharmacology [database online]. Available at: <http://www.clinicalpharmacology.com>. Accessed March 5, 2014.
- 12 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 13 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 14 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 15 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 16 Gold Standard, Inc. Epinephrine. Clinical Pharmacology [database online]. Available at: <http://www.clinicalpharmacology.com>. Accessed March 5, 2014.
- 17 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 18 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 19 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 20 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 21 Gold Standard, Inc. Epinephrine. Clinical Pharmacology [database online]. Available at: <http://www.clinicalpharmacology.com>. Accessed March 5, 2014.
- 22 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 23 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 24 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 25 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 26 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 27 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 28 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 29 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 30 EpiPen/EpiPen Jr. [package insert]. Columbia, MD; Mylan; August 2012.
- 31 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 32 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.
- 33 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 34 Lieberman P, Nicklas RA, Oppenheimer J, Kemp SR, Lang DM, et al. Diagnosis and management of anaphylaxis practice parameter: 2010 update (article in press). *J Allergy Clin Immunol.* 2010; doi:10.1016/j.physlethb.2003.10.071. Available at: <http://www.aaaai.org/practice-resources/Statements-and-Practice-Parameters/Practice-parameters-and-other-guidelines-page.aspx>. Accessed March 5, 2014.
- 35 EpiPen/EpiPen Jr [package insert]. Columbia, MD; Mylan; August 2012.
- 36 Auvi-Q [package insert]. Bridgewater, NJ; Sanofi-Aventis; September 2012.
- 37 Epinephrine injection [package insert]. Horsham, PA; Lineage Therapeutics; April 2013.
- 38 Adrenaclick [package insert]. Horsham, PA; Amedra; April 2013.